The results of this study show that the addition of capivasertib to fulvestrant therapy significantly improved progression-free survival in participants with oestrogen receptor-positive HER2-negative breast cancer that had progressed on an aromatase inhibitor. The gene discussed is CYP19A1; the disease is breast cancer.